Medical marijuana
Between a plant and a hard place
Abstract
Medical marijuana (MMJ) is a multifaceted and complicated issue involving far too much information to convey in a single review article. In this article, we touch on points that we hope will help the practitioner make more informed decisions about the use of MMJ in the field of neurology. In particular, we discuss the systematic review published in Neurology® and describe the 2 agents that have been approved for general use by the US Food and Drug Administration (FDA). In addition, we address quality assurance, prescribing, and legal concerns and provide information about the use of Epidiolex, a liquid formulation of highly purified cannabidiol (CBD) extract, as a treatment for various orphan pediatric epilepsy syndromes.
Get full access to this article
View all available purchase options and get full access to this article.
Supplementary Material
File (appendix_e-1.docx)
- Download
- 12.22 KB
REFERENCES
1.
Koppel BS, Brust JC, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014;82:1556–1563.
2.
Armstrong MJ, Miyasaki JM; American Academy of Neurology. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 2012;79:597–603.
3.
Proal AC, Fleming J, Galvez-Buccollini JA, Delisi LE. A controlled family study of cannabis users with and without psychosis. Schizophr Res 2014;152:283–288.
4.
US Food and Drug Administration. “Off-label” and investigational use of marketed drugs, biologics, and medical devices—information sheet. Available at: http://www.fda.gov/RegulatoryInformation/Guidances/ucm126486.htm. Accessed February 20, 2015.
5.
Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R. Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci 2006;95:1308–1317.
6.
Jones RT. Human effects: an overview. In:, Peterson RC, editor. Marijuana Research Findings: 1980. Rockville, MD: National Institute on Drug Abuse; 1980:54–80. NIDA Research Monograph 31, June 1980.
7.
McConnell BV, Applegate M, Keniston A, Kluger B, Maa EH. Use of complementary and alternative medicine in an urban county hospital epilepsy clinic. Epilepsy Behav 2014;34:73–76.
8.
Jusko WJ, Gardner MJ, Mangione A, Schentag JJ, Koup JR, Vance JW. Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol. J Pharm Sci 1979;68:1358–1366.
9.
Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014;55:791–802.
10.
Conant v Walters (9th Cir 2002) 309 F.3d 629, cert denied Oct. 14, 2003.
11.
US Department of Justice, Office of the Deputy Attorney General David W. Ogden. Memorandum for selected United States attorneys: investigations and prosecutions in states authorizing the medical use of marijuana. Published October 19, 2009. Available at: http://blogs.justice.gov/main/archives/192. Accessed June 29, 2014.
12.
US Department of Justice, Office of the Deputy Attorney General James M. Cole. Memorandum for all United States attorneys: guidance regarding marijuana enforcement. Published August 29, 2013. Available at: http://www.justice.gov/iso/opa/resources/3052013829132756857467.pdf. Accessed June 29, 2104.
13.
US Department of Justice, Office of the Deputy Attorney General James M. Cole. Memorandum for all United States attorneys: guidance regarding marijuana related financial Crimes. Published February 14, 2014. Available at: http://www.justice.gov/usao/waw/press/newsblog%20pdfs/DAG%20Memo%20-%20Guidance%20Regarding%20Marijuana%20Related%20Financial%20Crimes%202%2014%2014%20(2).pdf. Accessed June 29, 2014.
14.
Vialpando v Ben's Auto. Servs., 2014 N.M. App. LEXIS 50 (N.M. Ct. App. May 19, 2014).
15.
Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav 2013;29:574–577.
Information & Authors
Information
Published In
Neurology® Clinical Practice
Volume 5 • Number 4 • August 2015
Pages: 281-284
Copyright
© 2015 American Academy of Neurology.
Publication History
Published in print: August 2015
Published online: August 6, 2015
Disclosures
D. Gloss serves as an evidence-based medicine consultant to the American Academy of Neurology; is a Level of Evidence Associate Editor for Neurology; and receives publishing royalties for Neurology for the Specialty Boards (Lippincott Williams and Wilkins, 2006). E. Maa has received funding for travel or speaker honoraria for a NINDS clinical trial methods course. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.
Study Funding
No targeted funding reported.
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Cannabinoid-Based Medicines and Multiple Sclerosis, Cannabinoids and Neuropsychiatric Disorders, (111-129), (2020).https://doi.org/10.1007/978-3-030-57369-0_8
- More Research Is Underway for Cannabinoids for Neurologic Disorders, Neurology Today, 19, 6, (1,20-21), (2019).https://doi.org/10.1097/01.NT.0000554703.36617.bf
- Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis, Medicines, 5, 3, (91), (2018).https://doi.org/10.3390/medicines5030091
- National Board Offers Guidance for Doctors Prescribing Medical Marijuana, Neurology Today, 16, 18, (17-19), (2016).https://doi.org/10.1097/01.NT.0000502833.81504.d7
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.